MBD2 and hepatocellular carcinoma: Liu et al. revealed that low basal circKCNN2 levels are associated with worse prognosis and tumor recurrence in HCC patients but also, on the other side, predispose them to the stronger antitumor effect of lenvatinib via the miR-520c-3p/MBD2 axis [94].